SUMMARY
In this analysis of 3,396 preclinical cardiovascular studies, women were first, senior, and both first and senior authors in 41.3%, 20.7%, and 11.0% of the studies, respectively. Female authorship increased over a 10-year period. However, the proportion of studies with first and senior authors of differing sex was low and stable, suggesting that segregation by sex in mentorship relationships exists and persists. Female authors were more likely to consider sex as a biological variable, but author sex was not associated with other measures of experimental rigor or research impact, indicating that women's underrepresentation was not due to differences in research capacity or impact. T he now outdated axiom that cardiovascular disease is a disease of men began to be meaningfully challenged in the 1980s, with considerable effort focused on adequately representing women in clinical trials. Central to many of these initiatives was (and continues to be) the recognition that fundamental yet poorly understood differences exist between men and women, and that these differences could engender health disparities if ignored.
However, this "revolution" has not permeated preclinical stages of research, which serve to inform clinical trials. The preferential use of male animals and a lack of sex-disaggregated reporting is increasing in cardiovascular science (1) , despite the emphasis of the National Institutes of Health (NIH) on considering sex in preclinical research as important for advancing the health of women (2) and despite its feasibility in most research settings (3) . This bias has the potential to undermine advances made in clinical trial design by skewing our understanding of disease processes and the effectiveness of potential therapies (4).
It has been argued that the participation of women in research enhances knowledge outcomes and scientific progress (5), in part via enhanced exploration of sex differences (6) . If true, sex gaps in medicine and research-including the underrepresentation of women in fields such as cardiology (7) and the relative lack of adequate mentorship for women (8)-would not only have important societal implications but also meaningful scientific ramifications. Recognizing this possibility, the NIH has emphasized their commitment to diversity in the biomedical research workforce (including better representation of women) and identified assessing the impact of this diversity on the quality and outputs of research as 1 of 4 major diversity challenges facing the biomedical "ecosystem" (9).
We therefore examined a large body of leading preclinical cardiovascular research to explore potential differences in experimental rigor between male and female researchers, focusing on the inclusion of female animals in experiments and on analyses of sex differences. Temporal trends in female authorship and patterns in mentorship relationships by sex were examined as secondary analyses. We hypothesized that female authorship and mentorship relationships between men and women had both increased, but that these would not be associated with increased consideration of sex as a biological variable or with other measures of experimental rigor. Pre-specified variables collected included the disease studied, the animal model(s) used and their sex, and whether any study result was reported by sex. Because of the possibility that differences in female animal inclusion or sex-specific analyses might be attributable to broader differences in experimental design, we also analyzed whether animals were randomized, whether blinding was used (concealed allocation or Labinaz et al.
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A U G U S T 2 0 1 9 : 4 7 1 -7 blinded outcome assessment), and whether sample size and/or power estimations were performed.
Study author names were extracted from Scopus.
Author sex was determined using the online database genderize.io, which included >216,000 first names across 79 countries and 89 languages when queried. All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina) using a 2-tailed a level of 0.05 (corrected using the Bonferroni method to account for multiple comparisons when specified). 
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A U G U S T 2 0 1 9 : 4 7 1 -7 comparisons (Figure 3) . The preceding differences persisted when female authorship was examined on an interval scale (per 10% increase) and after adjusting for pre-specified potential confounders ( Table 1 ).
All findings were also comparable in sensitivity analyses using a minimum certainty factor of 90% for A corollary to the previously described findings is that the persistent underrepresentation of women in preclinical cardiovascular research is highly unlikely to be attributable to differences in research capacity or potential impact. Rather, systemic factors are probably influential. For instance, although modern scientific endeavors are increasingly reliant on research teams and networks-settings in which a diversity of viewpoints and experiences are sought However, they might not be representative of all preclinical cardiovascular journals. Author sex was determined using an arbitrary certainty factor, which might have resulted in misclassification in a minority of cases. However, our results were comparable in sensitivity analyses using a more stringent criterion. Our analysis did not capture instances of multiple first or corresponding authors (equally contributing authors) and used author position as a proxy for mentorÀmentee relationships.
Presumed author sex might not reflect author gender, which might be a relevant distinction in our analysis. Our analysis also focused on experimental and reporting standards proposed by the NIH, which were not exhaustive. Labinaz et al. 
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